Navigation Links
Oligomerix, Inc. Completes Series B Financing
Date:5/22/2013

ts to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:
Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

Tiberend Strategic Advisors, Inc. 
Andrew Mielach
212-375-2694
amielach@tiberend.com


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
3. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
4. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
5. bioRASI Completes Acquisition of Ukrainian CRO
6. Novira Therapeutics Completes $25 Million Series A Financing
7. BGI-Shenzhen Completes Acquisition of Complete Genomics
8. Amarantus Completes Name Change and CUSIP Change
9. Advanced Cell Diagnostics Completes $12 Million Series B Financing
10. Synthetic Biologics Completes $10.8 Million Private Placement Financing
11. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... with certain shareholders representing approximately 45% of the outstanding ... certain matters including the appointment of auditors at its ... 2015 (the "Meeting") it intends to adjourn the Meeting ... when the Meeting reconvenes. The Meeting will be reconvened ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... SHANGHAI , CAMBRIDGE, Mass. and ... -- WuXi NextCODE, which provides comprehensive capabilities for using the ... deCODE genetics on their publication of the largest studies of ... published today online in Nature Genetics ... date of sequence variation, authored by a team of deCODE ...
(Date:3/25/2015)... San Francisco, CA (PRWEB) March 25, 2015 ... Provide Support for Novel Mechanism of Action in ... March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) ... its fast skeletal muscle troponin activator tirasemtiv in ... from a Phase IIa “Evidence of Effect” or ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... , , ... , , , ... example protein arrays) or as biopharmaceutical therapeutics. In,all cases the ... key quality criteria include: protein identification,quantitation and the monitoring of ...
... , ... , , , When working ... transfection of small interfering RNA (siRNA),into a cell, the presence of having ... be of great value.,Three to four siRNA sequences are generally tested for ...
... , , ... , , This Application Note ... can be used to detect cell surface,and intracellular protein targets by ... on CCRF-CEM cells and intracellular,glucocorticoid receptor (GR) staining of H4 rat ...
Cached Biology Technology:Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 2Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 3siRNA transfection optimization,with the Agilent 2100 bioanalyzer 2siRNA transfection optimization,with the Agilent 2100 bioanalyzer 3siRNA transfection optimization,with the Agilent 2100 bioanalyzer 4siRNA transfection optimization,with the Agilent 2100 bioanalyzer 5siRNA transfection optimization,with the Agilent 2100 bioanalyzer 6siRNA transfection optimization,with the Agilent 2100 bioanalyzer 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 2Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 3Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 4Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 5Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 6Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 8
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2
... detection is critical for improving cancer survival rates. Yet, ... lung cancer, is notoriously difficult to detect in its ... to detect lung cancer by merely shining diffuse light ... new clinical study, the analysis technique--called partial wave spectroscopic ...
... Many scientists aspire to take control over the stem cell ... perfectly matched to each patient in the future. Now research ... SAGE-Hindawi, explains how engineering the topography on which stem cells ... as powerful an agent for change as their chemical environment. ...
... BOZEMAN, Mont. -- Invasive plants make life tougher for ... of the Missouri River Basin, so why not turn the ... time? Russian olive and saltcedar alone could supply biomass ... region. Converting invasive plants to fuel is an ...
Cached Biology News:Cheek swab may detect lung cancer 2Cheek swab may detect lung cancer 3Stem cells shape up to their surroundings 2Stem cells shape up to their surroundings 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... Assay Kit contains all reagents necessary to ... lineage, as determined by staining for mineralization. ... necessary reagents and a protocol for quantifying ... product is useful for studying the effects ...
... discovery races ever faster, you need a partner ... So our constant focus is on providing tools ... why our Biomek 3000 Laboratory Automation Workstation offers ... it is flexible. By integrating all aspects of ...
Biology Products: